| Primary Identifier | MGI:3691946 | Allele Type | Transgenic |
| Attribute String | Dominant negative, Inducible, Inserted expressed sequence, Reporter | Gene | Tg(tetO-EGFP,-Tgfbr2)8Mcle |
| Strain of Origin | FVB/N | Induced With | doxycycline/tetracycline |
| Is Recombinase | false | Is Wild Type | false |
| description | Of 17 transgenic mice derived from microinjected oocytes, 6 yielded cell cultures that strongly expressed EGFP upon transfection with a tetracycline transactivator- (tTA-; "tet-off") expressing plasmid. Offspring of two transgenic founder lines, designated by the authors PTRe and PTRh, by tTA transgenic mice were subjected to further expression analysis. |
| molecularNote | The transgene comprises a bidirectional tetracycline transactivator responsive promoter (tetO) between an enhanced green fluorescent protein gene with a polyadenylation (poly[A]) signal derived from simian virus 40 (SV40) and a truncated transforming growth factor, beta receptor II cDNA with a c-Myc epitope tag and a beta-globin gene-derived poly[A] signal. The encoded TGFBR2 protein, which lacks the intracellular kinase domain, functions as a dominant-negative receptor, disrupting TGFbeta signaling. Tissues of transgenic mice do not fluoresce. Coordinate expression of EGFP and dominant-negative TGFBR2 can be regulated in a tissue-specific manner in bitransgenic mice with this and a tetracycline transactivator (tTA; "tet-off") or reverse transactivator (rtTA; "tet-on") transgene by administration/withdrawal of the tetracycline analog doxycycline. |
